Literature DB >> 22819262

The search for genetic mouse models of prodromal Parkinson's disease.

Gaynor A Smith1, Ole Isacson, Stephen B Dunnett.   

Abstract

Parkinson's disease is characterized and diagnosed by bradykinetic motor symptoms caused by the loss of dopamine neurons in the substantia nigra. The pathological and non-motor behavioral changes that occur prior to degeneration are less well characterized, although changes in gait, olfaction and cognition have been recognized in familial Parkinson's disease subjects. Gene mutations associated familial Parkinson's disease give rise to mitochondrial changes, altered energy homeostasis and intracellular trafficking deficits, and these can be modeled in transgenic mice. Here we discuss the recent finding of prodromal behavioral disturbances in a PINK1 deficient mouse that manifest prior to dopaminergic cell death and correlate to 5-HT fiber losses and mitochondrial morphological changes. We discuss the representation of the PINK1 deficient mouse and other genetic models to accurately recapitulate early Parkinson's disease. Prodromal symptoms and underlying pathology modeled in mice and cell lines from human subjects may have wide implications for earlier diagnosis. Current and emerging therapies need to be tailored to target both early cognitive and late stage motor symptoms. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819262     DOI: 10.1016/j.expneurol.2012.06.035

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  12 in total

Review 1.  Evaluating and responding to mitochondrial dysfunction: the mitochondrial unfolded-protein response and beyond.

Authors:  Cole M Haynes; Christopher J Fiorese; Yi-Fan Lin
Journal:  Trends Cell Biol       Date:  2013-03-13       Impact factor: 20.808

2.  Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.

Authors:  Jason R Cannon; Kindiya D Geghman; Victor Tapias; Thomas Sew; Michelle K Dail; Chenjian Li; J Timothy Greenamyre
Journal:  Exp Neurol       Date:  2012-11-12       Impact factor: 5.330

Review 3.  Parkinson's disease: experimental models and reality.

Authors:  Peizhou Jiang; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2017-11-18       Impact factor: 17.088

4.  Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.

Authors:  G A Smith; J Jansson; E M Rocha; T Osborn; P J Hallett; O Isacson
Journal:  Mol Neurobiol       Date:  2015-09-23       Impact factor: 5.590

5.  PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.

Authors:  Graziella Madeo; Tommaso Schirinzi; Giuseppina Martella; E Claudio Latagliata; Francesca Puglisi; Jie Shen; Enza Maria Valente; Mauro Federici; Nicola B Mercuri; Stefano Puglisi-Allegra; Paola Bonsi; Antonio Pisani
Journal:  Mov Disord       Date:  2013-10-25       Impact factor: 10.338

6.  Low-Expressing Synucleinopathy Mouse Models Based on Oligomer-Forming Mutations and C-Terminal Truncation of α-Synuclein.

Authors:  Ana Martinez Hernandez; Ivan Silbern; Insa Geffers; Lars Tatenhorst; Stefan Becker; Henning Urlaub; Markus Zweckstetter; Christian Griesinger; Gregor Eichele
Journal:  Front Neurosci       Date:  2021-06-17       Impact factor: 4.677

7.  Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?

Authors:  María C Leal; Juan C Casabona; Mariana Puntel; Fernando J Pitossi
Journal:  Front Cell Neurosci       Date:  2013-04-29       Impact factor: 5.505

8.  Loss of PINK1 enhances neurodegeneration in a mouse model of Parkinson's disease triggered by mitochondrial stress.

Authors:  Nicoleta Moisoi; Valentina Fedele; Jennifer Edwards; L Miguel Martins
Journal:  Neuropharmacology       Date:  2013-10-23       Impact factor: 5.250

Review 9.  Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.

Authors:  Honglei Chen; Edward A Burton; G Webster Ross; Xuemei Huang; Rodolfo Savica; Robert D Abbott; Alberto Ascherio; John N Caviness; Xiang Gao; Kimberly A Gray; Jau-Shyong Hong; Freya Kamel; Danna Jennings; Annette Kirshner; Cindy Lawler; Rui Liu; Gary W Miller; Robert Nussbaum; Shyamal D Peddada; Amy Comstock Rick; Beate Ritz; Andrew D Siderowf; Caroline M Tanner; Alexander I Tröster; Jing Zhang
Journal:  Environ Health Perspect       Date:  2013-08-09       Impact factor: 9.031

Review 10.  Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease.

Authors:  Daniela Maria Vogt Weisenhorn; Florian Giesert; Wolfgang Wurst
Journal:  J Neurochem       Date:  2016-06-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.